Continuous daily sunitinib for recurrent glioblastoma

Journal of Neuro-Oncology

Volumn 111, Issue 1, 2013, Pages 41-48

  Kreisl, Teri Nguyen ^a   Smith, Perry ^a   Sul, Joohee ^a   Salgado, Carlos ^a   Iwamoto, Fabio M ^a   Shih, Joanna H ^a   Fine, Howard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Bevacizumab; FDG PET; Glioblastoma; Sunitinib

Indexed keywords

BEVACIZUMAB; FLUORODEOXYGLUCOSE; SUNITINIB;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER RESISTANCE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DOSE RESPONSE; DRUG DOSE REDUCTION; EPISTAXIS; EVENING DOSAGE; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECTUM HEMORRHAGE; RECURRENT CANCER; SKIN BRUISING; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRROLES; QUALITY OF LIFE; SURVIVAL RATE;

EID: 84871816644     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0988-z     Document Type: Article

References (15)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996. doi: 10.1056/NEJMoa043330
2. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740-745. doi: 10.1200/JCO.2008.16.3055
3. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73(15):1200-1206. doi: 10.1212/WNL.0b013e3181bc0184
4. Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7(12):1152-1160. doi: 10.1016/S1474-4422(08) 70260-6
5. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25(7):884-896. doi: 10.1200/JCO.2006.06.3602
6. de Bouard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS (2007) Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 9(4):412-423. doi: 10.1215/15228517-2007-024
7. Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J, Tynninen O, Nupponen N, Michotte A, De Greve J (2011) Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 103(3):491-501. doi: 10.1007/s11060-010-0402-7
8. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963-1972. doi: 10.1200/JCO.2009.26.3541
9. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75(5):1151-1161
10. Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol 13(10):1143-1150. doi: 10.1093/neuonc/nor091
11. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9(1):29-38. doi: 10.1215/15228517-2006-025
12. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740. doi: 10.1200/JCO.2008.19.8721
13. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66(2):357-371. doi: 10.1007/s00280-009-1170-y
14. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY (2011) Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer. doi: 10.1002/cncr.26440
15. Goldlust SA, Cavaliere R, Newton HB, Hsu M, Deangelis LM, Batchelor TT, Gilbert MR, Lassman AB (2011) Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. J Neurooncol. doi: 10.1007/s11060-011-0768-1